Welcome to our dedicated page for Design Therapeutics SEC filings (Ticker: DSGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Design Therapeutics, Inc. filings document the regulatory disclosures of a Nasdaq-listed, clinical-stage biotechnology company developing GeneTAC® small-molecule therapies for serious degenerative genetic diseases. Its 8-K reports furnish financial results, corporate presentations, pipeline updates, and material governance events tied to board appointments, resignations, committee assignments, director compensation, and indemnification arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, stockholder voting procedures, and board structure. The filing record also identifies the company’s common stock registration on The Nasdaq Global Select Market, emerging growth company status, and public-company disclosure framework for operations, capital structure, governance, and risk reporting.
Design Therapeutics reported a board change effective September 9, 2025. Director Arsani William, M.D. resigned from the board, and the company stated his resignation was not due to any disagreement over operations, policies, or practices.
On the same date, the board appointed Justin Gover as a Class III director with a term running through the 2027 annual meeting of stockholders. He was also named chair of the Compensation Committee. Under the company’s non-employee director compensation policy, he will receive annual cash retainers of $40,000 for board service and $12,000 for serving as Compensation Committee chair, plus stock options to purchase 30,000 shares vesting over three years and a prorated annual option for 15,833 shares vesting over one year.
Point72 affiliates reported ownership of 2,942,719 shares of Design Therapeutics, Inc. (CUSIP 25056L103), representing 5.2% of the outstanding common stock as of the close of business on August 27, 2025. The filing states that Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. share voting and dispositive power over these shares, and that Steven A. Cohen exercises control of those entities. Point72 Associates is identified as the fund holding the shares and has the right to receive dividends or sale proceeds. The filing includes a joint filing agreement as Exhibit 99.1 and lists principal business and issuer addresses.
Design Therapeutics director William Arsani reported sales of company common stock on 08/13/2025. The Form 4 shows two dispositions executed at $5.25 per share: 345,000 shares sold by Logos Global Master Fund LP and 217,627 shares sold by Logos Opportunities Fund II LP. After the sales, the filing reports 2,655,000 shares beneficially owned by Logos Global Master Fund LP and 1,000,000 shares beneficially owned by Logos Opportunities Fund II LP. Arsani is identified as a director and the filing disclaims direct beneficial ownership except to the extent of a pecuniary interest through the reported funds. The form is signed by an attorney-in-fact on 08/14/2025.
Design Therapeutics reported a Form 144 notice proposing the sale of 217,627 common shares, with an aggregate market value of $1,083,783.00, scheduled approximately for 08/13/2025 on NASDAQ through broker BTIG, LLC. The filing shows the shares were originally acquired on 01/25/2021 in a private market transaction from Design Therapeutics, with 1,984,733 shares acquired and paid in cash on that date. The filer reports no securities sold in the past three months and affirms they are unaware of any undisclosed material adverse information about the issuer.
Design Therapeutics filed a Form 144 reporting a proposed sale of 345,000 common shares through BTIG, LLC with an aggregate market value of $1,718,100.00. The filing lists 56,900,000 shares outstanding and shows the shares were acquired on 03/26/2021 in the open market (700,000 acquired) with cash payment.
The Form 144 indicates an approximate sale date of 08/13/2025, notes nothing to report for securities sold in the past three months, and includes the filers representation that they are not aware of any undisclosed material adverse information about the issuer.